Bibliografía del artículo
[1] Pardine DP. – Sindrome do Climatério: Terapêutica Atual. Arq Bras Endocinol Metab 1992; 36: 67. [2] Melo NR, Fernandes CE, Piompei LM, Wehba S. – Climatério como diagnosticar e lidar. Rev Bras Med 1997; 54: 67. [3] Lindsay R, Hart DM, Aitken JM, Macdonald EB, Anderson JB, Clarke AC. – Long-term prevention of postmenopausal osteoporosis by estrogen. Evidence for an increased bone mass after delayed onset of estrogen treatment. Lancet 1976; 1(7968): 1038. [4] Khaw KT. – Epidemiology of the menopause. Br Med Bull 1992; 48: 249. [5] Daly E, Roche M, Barlow D, Gray A, Mcpherson K, Vessey M. – HRT: An analysis of benefits, risks and costs. Br Med Bull 1992; 48: 368. [6] Belchetz PE. – Hormonal treatment of postmenopausal women. N Engl J Med 1994; 330: 1062. [7] Wild RA. – Risk factors: assessment and preventive measures. Clin Obstet Gynecol 1998; 41: 966. [8] Barlow DH. – Hormone replacement therapy and other menopause associated conditions. Br. Med. Bull., 48: 356, 1992. [9] Nachtigall LE. – The symptoms of perimenopause. Clin Obstet Gynecol 1998; 41: 921. [10] Grady D, Herrington D, Bitter V, Blumenthal R, Davidson M, Hlatky M. for a HERS Research Group. Cardiovascular disease outcomes during 6.8 yars of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 49. [11] Grady D, Yaffe K, Kristof M, Lin F, Richards C, Barrette-Connor E. – Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study. Am J Med 2002; 113: 543. [12] Herrington DM, Vittinghoff E, Howard TD, Major DA, Owen J, Reboussin DM. – Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Artherioscler Tromb Vasc Biol 2002; 22: 1012. [13] Rossouw JE, Anderson GL, Prentice RL, La Croix AZ, Kooperberg C, Stefanick ML. – Writing Group for the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321. [14] Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL. for the Women’s Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart diasease. N Engl J Med 2003; 349: 523. [15] Han KK, Soares Jr JM, Haidar MA, Rodrigues De Lima G, Baracat EC. – Benefits of Soy Isoflavone Therepeutic Regimen on Menopausal Symptoms. Obstet Gynecol 2002; 99: 389. [16] Kaari C, Haidar MA, Soares Jr JM, Nunes MG, Quadros LGA, Kemp C, Stavale JN, Baracat EC. – Randomized Clinical Trial Comparing Conjugted Equine Estrogens and Isoflavones in Postmenopausal Women: A Pilot Study. Maturitas 2006; 53: 49.